HANSOH PHARMA (03692): Amelec (Ametisulphate Amelecine Tablets) obtained the fifth indication of the National Medical Products Administration's drug registration certificate.

Hansoh Pharma (03692) announced that its innovative drug Amelec (Ameitinib mesylate tablets) has been granted a drug registration certificate by the National Medical Products Administration of China (NMPA). It has been approved for the indication of "Amelec in combination with Pembrolizumab and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have exon 19 deletion or exon 21 (L858R) substitution mutations in the epidermal growth factor receptor (EGFR)." This is the fifth indication for which Amelec has been approved.